Serina Therapeutics (Serina Therapeutics) Debt-to-EBITDA : 1.47 (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Serina Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $7.81 Mil. Serina Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.39 Mil. Serina Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2023 was $5.58 Mil. Serina Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 1.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Serina Therapeutics's Debt-to-EBITDA or its related term are showing as below:

SER' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69 Med: -0.51 Max: 5.23
Current: 5.23

During the past 2 years, the highest Debt-to-EBITDA Ratio of Serina Therapeutics was 5.23. The lowest was -0.69. And the median was -0.51.

SER's Debt-to-EBITDA is ranked worse than
81.29% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs SER: 5.23

Serina Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Serina Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Debt-to-EBITDA Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Debt-to-EBITDA

-0.32

-0.69

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Debt-to-EBITDA	N/A	-	-0.74	1.47

Competitive Comparison of Serina Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Serina Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Debt-to-EBITDA falls into.

Serina Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Serina Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.128	+	1.68)	/	-2.605
	=	-0.69

Serina Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(7.805	+	0.388)	/	5.582
	=	1.47

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

Serina Therapeutics (AMEX:SER) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Serina Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024